1. Home
  2. NHS vs FHTX Comparison

NHS vs FHTX Comparison

Compare NHS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

HOLD

Current Price

$7.23

Market Cap

218.5M

Sector

Finance

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.36

Market Cap

247.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHS
FHTX
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.5M
247.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NHS
FHTX
Price
$7.23
$4.36
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$11.86
AVG Volume (30 Days)
111.8K
185.9K
Earning Date
01-01-0001
11-05-2025
Dividend Yield
13.44%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$24,518,000.00
Revenue This Year
N/A
$47.50
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.95
$2.95
52 Week High
$9.17
$6.79

Technical Indicators

Market Signals
Indicator
NHS
FHTX
Relative Strength Index (RSI) 42.96 47.41
Support Level $7.22 $4.33
Resistance Level $7.34 $4.59
Average True Range (ATR) 0.06 0.25
MACD 0.01 -0.02
Stochastic Oscillator 41.98 20.00

Price Performance

Historical Comparison
NHS
FHTX

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: